PHARMACEUTICAL COMPOSITION COMPRISING ANTI-CTLA4-ANTI-PD-1 BISPECIFIC ANTIBODY AND CHIAURANIB

Abstract: the present invention belongs to the fields of tumor treatment and molecular immunology, and relates to a pharmaceutical composition comprising an anti-ctla4-anti-pd-1 bispecific antibody and chiauranib. specifically, the pharmaceutical composition comprises chiauranib or a pharmaceutically acceptable salt thereof or a crystalline form thereof, and at least one anti-ctla4-anti-pd-1 bispecific antibody. the present invention also relates to use of the pharmaceutical composition.

Inventor(s): Yu XIA, Xianping LU, Baiyong LI, Zhiqiang NING, Zhongmin WANG, Desi PAN

CPC Classification: C07K16/2818 (PEPTIDES (peptides in foodstuffs ; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs ; preparations for medicinal purposes ; peptides containing beta-lactam rings ; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, ; ergot alkaloids of the cyclic peptide type ; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids ; macromolecular products derived from proteins ; preparation of glue or gelatine ; single cell proteins, enzymes ; genetic engineering processes for obtaining peptides ; compositions for measuring or testing processes involving enzymes ; investigation or analysis of biological material ))

Search for rejections for patent application number 20250188164